NCT02386800 2026-03-16
CINC424A2X01B Rollover Protocol
Novartis
Phase 4 Active not recruiting
Clinical Trials
107 trialsNCT04804709 2025-06-08
Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive Diffuse Midline Glioma (DMG)
Columbia University
Phase 1 Terminated
NCT01324635 2025-05-02
Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors
Thomas Jefferson University
Phase 1 Terminated
NCT02506959 2025-03-18
Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04897880 2025-02-24
NORTH
Australian & New Zealand Children's Haematology/Oncology Group
Phase 2 Terminated
NCT02654990 2024-07-12
PANORAMA_3
pharmaand GmbH
Phase 2 Completed
NCT04956302 2024-06-06
Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
Ohio State University Comprehensive Cancer Center
Phase 1 Terminated
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT04341311 2024-02-15
DIPG
Dana-Farber Cancer Institute
Phase 1 Terminated
NCT01238692 2023-03-24
A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL)
Jewish General Hospital
Phase 2 Completed
NCT05725200 2023-02-21
EVIDENT
Oslo University Hospital
Phase 2 Recruiting
NCT04326764 2023-02-16
Panobinostat Maintenance After HSCT fo High-risk AML and MDS
Goethe University
Phase 3 Terminated
NCT02032810 2023-01-20
Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02890069 2023-01-11
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Novartis
Phase 1 Completed
NCT02722941 2022-11-01
Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT01582009 2022-08-15
Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate
Roswell Park Cancer Institute
Phase 1/2 Terminated
NCT01261247 2022-05-24
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Mayo Clinic
Phase 2 Completed
NCT03256045 2022-05-09
Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
University of Washington
Phase 2 Terminated
NCT01658241 2022-05-06
VEG VCA1
Peter MacCallum Cancer Centre, Australia
Phase 2 Completed
NCT00550277 2021-11-23
LBH589 Treatment for Refractory Clear Cell Renal Carcinoma
SCRI Development Innovations, LLC
Phase 2 Completed
NCT01965353 2021-09-05
PanRVD
Dana-Farber Cancer Institute
Phase 1 Completed
NCT00742027 2021-07-28
Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma
Novartis
Phase 2 Completed
NCT00449761 2021-07-15
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase
Novartis
Phase 2 Terminated
NCT00445068 2021-07-14
Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma
Novartis
Phase 2 Terminated
NCT00667862 2021-06-21
Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate Cancer
Novartis
Phase 2 Completed
NCT00936611 2021-01-28
LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01169636 2021-01-06
Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00493766 2020-12-19
Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone
Novartis
Phase 1 Terminated
NCT00503451 2020-12-19
A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT00532675 2020-12-19
Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.
Novartis
Phase 1 Completed
NCT00570284 2020-12-19
A Study to Investigate the Effect of Food on Oral LBH589 Absorption in Patients With Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT00739414 2020-12-19
Dose-escalating Study of LBH589 in Adult Patients With Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT00788931 2020-12-19
A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer
Novartis
Phase 1 Completed
NCT00997399 2020-12-19
Study to Evaluate Panobinostat (DACi) Pharmacokinetics and Safety in Solid Tumors and Varying Renal Function
Novartis
Phase 1 Completed
NCT01242774 2020-12-19
Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)
Novartis
Phase 1 Completed
NCT01613976 2020-12-19
A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients
Novartis
Phase 1 Completed
NCT00823290 2020-12-14
Sorafenib and LBH589 in Hepatocellular Carcinoma (HCC)
University of Erlangen-Nürnberg Medical School
Phase 1 Terminated
NCT00946647 2020-08-04
A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).
Novartis
Phase 1/2 Completed
NCT01023308 2020-03-17
PANORAMA-1
Novartis
Phase 3 Completed
NCT00918333 2020-03-10
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma
Mayo Clinic
Phase 1/2 Completed
NCT02057640 2019-12-11
MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma
Case Comprehensive Cancer Center
Phase 1/2 Completed
NCT00985946 2019-12-09
Study of Panobinostat in Patients With Neuroendocrine Tumors
University of Wisconsin, Madison
Phase 2 Terminated
NCT01013597 2019-11-29
Trial of LBH589 in Metastatic Thyroid Cancer
University of Wisconsin, Madison
Phase 2 Completed
NCT01523834 2019-11-22
FIL_PanAL10
Fondazione Italiana Linfomi - ETS
Phase 2 Completed
NCT02290431 2019-11-18
Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma
Novartis
Phase 2 Completed
NCT01463046 2019-04-22
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
University of California, San Francisco
Phase 1 Completed
NCT02518750 2019-04-03
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT01440582 2019-03-04
Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01549431 2019-01-16
Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma
Emory University
Phase 1 Completed
NCT00840346 2018-12-11
PANOBIDARA
PETHEMA Foundation
Phase 1/2 Completed